Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA), Prof Boris Hadaschik (University of Duisburg-Essen, Essen, Germany) and Prof Gerhardt Attard (University College London: Cancer Institute, London, UK) discuss the updates in prostate cancer from ESMO 2022.
They start by discussing the STAMPEDE trial. They then talk about the biomarker analysis and updated results from the phase III PROpel trial of abiraterone and olaparib versus abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer.
Prof Attard and Prof Hadaschik then comment on the updated data from the PEACE1 phase III trial.
Prof Efstathiou mentions the IMPROVE trial which is an investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide versus enzalutamide alone.
The panel talks about androgen annihilation in patients with high-risk biochemically relapsed prostate cancer (AFT-19). They conclude by discussing the CABASTY randomised phase III trial.